Background: Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of hematological malignancies, yet its application in solid tumors remains constrained by unique biological and logistical barriers. Objective: This review critically examines the evolving landscape of CAR T-cell therapy in solid malignancies, with a focus on antigen heterogeneity, the immunosuppressive tumor microenvironment, and risks of on-target, off-tumor toxicity. Methods: We outline recent advances in CAR engineering, including co-stimulatory optimization, dual- and multi-antigen targeting, armored CARs, and gene-edited constructs designed to enhance persistence and anti-tumor activity. Clinical progress is highlighted by recent FDA approvals of genetically modified T-cell therapies in synovial sarcoma and melanoma, underscoring the potential for broader solid tumor application. Additionally, we synthesize early-phase clinical trial findings across multiple solid tumor types (e.g., lung, colorectal, ovarian, glioblastoma), and discuss innovative approaches such as regional delivery, checkpoint blockade combinations, and incorporation of chemokine receptors for improved tumor infiltration. The review also considers future strategies, including artificial intelligence-guided target discovery and rational trial design to overcome translational bottlenecks. Conclusions: With expanding clinical experience and continued technological innovation, CAR T-cell therapy is steadily transitioning from an experimental strategy to a therapeutic reality in solid tumors, poised to reshape the future of cancer immunotherapy.

This review is the most comprehensive review of breast cancer in the United Arab Emirates to date.

Breast cancer stands as the prevailing malignancy across all six Gulf Cooperation Council (GCC) nations. In this literature review, we highlighted the incidence and trend of breast cancer in the GCC. Most of the studies reported a consistent increase in breast cancer incidence over the past decades, which was particularly attributed to the adoption of a Westernized lifestyle in the region and the implications of emerging risk factors and other environmental and societal factors, the increase in screening uptake, as well as the improvement in data collection and reporting in the GCC. The data on breast cancer risk factors in the GCC were limited. In this geographic region, breast cancer frequently manifests with distinctive characteristics, including an early onset, typically occurring before the age of 50; an advanced stage at presentation; and a higher pathological grade. Additionally, it often exhibits more aggressive features such as human epidermal growth factor receptor 2 (HER2) positivity or the presence of triple-negative (TN) attributes, particularly among younger patients. Despite the growing body of literature on breast cancer in the GCC, data pertaining to survival rates are, regrettably, meager. Reports on breast cancer survival rates emanating from the GCC region are largely confined to Saudi Arabia and the United Arab Emirates (UAE). In the UAE, predictive modeling reveals 2-year and 5-year survival rates of 97% and 89%, respectively, for the same period under scrutiny. These rates, when compared to Western counterparts such as Australia (89.5%) and Canada (88.2%), fall within the expected range. Conversely, Saudi Arabia reports a notably lower 5-year survival rate, standing at 72%. This disparity in survival rates underscores the need for further research directed toward elucidating risk factors and barriers that hinder early detection and screening. Additionally, there is a pressing need for expanded data reporting on survival outcomes within the GCC. In sum, a more comprehensive and nuanced understanding of breast cancer dynamics in this region is imperative to inform effective strategies for prevention, early detection, and improved patient outcomes.

The United Arab Emirates (UAE) has one of the fastest growing economies in the world, which has resulted in an increase in the detection of noncommunicable diseases such as cancer. Despite its screening and early detection efforts falling short of the target coverage of the intended population, the number of reported cases and deaths in UAE has increased over the years. A few studies have been conducted to understand the hurdles to cancer screening in UAE, mostly focusing on breast and colorectal malignancies. There are no studies or surveys that have addressed the barriers and hurdles to overall cancer screening in UAE’s population. Through this is the largest survey to date, we aimed at assessing UAE society’s perception of cancer and early screening and detection. The survey was constructed using the SurveyPlanet platform. The survey was then distributed on social media for direct and snowball sampling, including Instagram, WhatsApp, LinkedIn, Meta (Facebook), and Twitter. Interestingly, 71.3% of the respondents reported that they were fine mentioning or discussing cancer, while 28.2% reported that they were not comfortable with it. Moreover, 91.8% of the respondents knew the meaning of the early detection or screening of cancer, while 8.2% did not. The ability of respondents to correctly identify different types of cancer screening varied. This study suggests that regulatory authorities need to raise more awareness about cancer, especially among younger generations, and create screening recommendations and guidelines that should include younger people. Lastly, hospitals, cancer charity organizations, educational institutes, and the media should address target audiences to raise cancer awareness among them.

Hematopoietic stem cell transplantation (HSCT) is increasingly indicated for various malignant and non-malignant diseases. In the United Arab Emirates (UAE), patients that could benefit from the procedure commonly need to seek medical care abroad in view of the lack of a comprehensive HSCT facility that could offer the full spectrum of interventions and monitoring protocols. This comes with considerable challenges related to coverage and logistics of travel. It also limits the continuity of clinical care, and presents inconvenience to patients who come from a different cultural background. In this article, we share our experiences and lessons learned during the establishment of the first comprehensive adult and pediatric HSCT unit in the UAE that is designed to cater for local citizens and residents, as well as neighboring countries facing similar availability challenges.

In 2020, breast cancer (BC) was the most diagnosed cancer worldwide, with 2.26 million new cases and 685,000 deaths. In the UAE, breast cancer was one of the leading causes of cancer deaths in 2021, with an estimated average of 9.64% of cancer deaths per year. The total number of breast cancer cases reported to the UAE National Cancer Registry among the UAE population was 1139, representing 20.3% of all malignant cases in 2021. This chapter will review published articles and research data from the United Arab Emirates (UAE) to learn more about the features and outcomes of breast cancer. It will also draw attention to current unmet needs in order to focus on resource allocation and future clinical and research initiatives.